Literature DB >> 12761581

A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells.

I Petak1, R Vernes, K S Szucs, M Anozie, K Izeradjene, L Douglas, D M Tillman, D C Phillips, J A Houghton.   

Abstract

Tumor necrosis factor related apoptosis inducing ligand (TRAIL) belongs to the Tumor necrosis factor (TNF) family of death-inducing ligands, and signaling downstream of TRAIL ligation to its receptor(s) remains to be fully elucidated. Components of the death-inducing signaling complex (DISC) and TRAIL signaling downstream of receptor activation were examined in TRAIL - sensitive and -resistant models of human rhabdomyosarcoma (RMS). TRAIL ligation induced DISC formation in TRAIL-sensitive (RD, Rh18, Rh30) and TRAIL-resistant RMS (Rh28, Rh36, Rh41), with recruitment of FADD and procaspase-8. In RD cells, overexpression of dominant-negative FADD (DNFADD) completely abolished TRAIL-induced cell death in contrast to dominant-negative caspase- 8 (DNC8), which only partially inhibited TRAIL-induced apoptosis, growth inhibition, or loss in clonogenic survival. DNC8 did not inhibit the cleavage of Bid or the activation of Bax. Overexpression of Bcl-2 or Bcl-xL inhibited TRAIL-induced apoptosis, growth inhibition, and loss in clonogenic survival. Bcl-2 and Bcl-xL, but not DNC8, inhibited TRAIL-induced Bax activation. Bcl-xL did not inhibit the early activation of caspase-8 (<4 h) but inhibited cleavage of Bid, suggesting that Bid is cleaved downstream of the mitochondria, independent of caspase-8. Exogenous addition of sphingosine also induced activation of Bax via a caspase-8-and Bid-independent mechanism. Further, inhibition of sphingosine kinase completely protected cells from TRAIL-induced apoptosis. Data demonstrate that in RMS cells, the TRAIL signaling pathway circumvents caspase-8 activation of Bid upstream of the mitochondria and that TRAIL acts at the level of the mitochondria via a mechanism that may involve components of the sphingomyelin cycle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761581     DOI: 10.1038/sj.cdd.4401232

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  10 in total

1.  Bone marrow derived mesenchymal stem/stromal cells transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro.

Authors:  Helga Barti-Juhasz; Rudolf Mihalik; Katalin Nagy; Giulia Grisendi; Massimo Dominici; Istvan Petak
Journal:  Haematologica       Date:  2011-03       Impact factor: 9.941

2.  Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.

Authors:  Katalin Nagy; Kinga Székely-Szüts; Kamel Izeradjene; Leslie Douglas; Mike Tillman; Helga Barti-Juhász; Massimo Dominici; Carlotta Spano; Gian Luca Cervo; Pierfranco Conte; Janet A Houghton; Rudolf Mihalik; László Kopper; István Peták
Journal:  Pathol Oncol Res       Date:  2006-09-23       Impact factor: 3.201

3.  Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner.

Authors:  Ingo H Engels; Gudrun Totzke; Ute Fischer; Klaus Schulze-Osthoff; Reiner U Jänicke
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

4.  Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin.

Authors:  Tanvi S Jani; Jennifer DeVecchio; Tapati Mazumdar; Akwasi Agyeman; Janet A Houghton
Journal:  J Biol Chem       Date:  2010-04-27       Impact factor: 5.157

Review 5.  Sphingosine kinase 1 in cancer.

Authors:  Linda A Heffernan-Stroud; Lina M Obeid
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

6.  Initial response to treatment was highly associated with the prognosis of childhood rhabdomyosarcoma: a retrospective analysis of a single center experience in Korea.

Authors:  Jeong A Park; Eun Kyung Kim; Hyoung Jin Kang; Hee Young Shin; Il Han Kim; Hyo Seop Ahn
Journal:  Cancer Res Treat       Date:  2008-09-30       Impact factor: 4.679

7.  Cell death pathways as therapeutic targets in rhabdomyosarcoma.

Authors:  Simone Fulda
Journal:  Sarcoma       Date:  2012-01-12

8.  Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models.

Authors:  Eva Rettinger; Vida Meyer; Hermann Kreyenberg; Andreas Volk; Selim Kuçi; Andre Willasch; Ewa Koscielniak; Simone Fulda; Winfried S Wels; Halvard Boenig; Thomas Klingebiel; Peter Bader
Journal:  Front Oncol       Date:  2012-04-09       Impact factor: 6.244

Review 9.  Radioresistance in rhabdomyosarcomas: Much more than a question of dose.

Authors:  Simona Camero; Matteo Cassandri; Silvia Pomella; Luisa Milazzo; Francesca Vulcano; Antonella Porrazzo; Giovanni Barillari; Cinzia Marchese; Silvia Codenotti; Miriam Tomaciello; Rossella Rota; Alessandro Fanzani; Francesca Megiorni; Francesco Marampon
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

10.  Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells.

Authors:  Zsuzsanna A Dunai; Gergely Imre; Gabor Barna; Tamas Korcsmaros; Istvan Petak; Pal I Bauer; Rudolf Mihalik
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.